Workshop on Building a Renal Denervation Program-SCAI Document on Operator Requirements: Who and What Training? Dr. Herb Aronow

SCAI Document on Operator Requirements: Who and What Training? Dr. Herb Aronow

Video Transcription

Video Summary

The video discusses the persistent issue of uncontrolled hypertension among adults in the U.S., with nearly 45% affected and only about 20% having controlled hypertension. The session reviews renal denervation (RDN), a procedure using radiofrequency or ultrasound to manage hypertension unresponsive to lifestyle changes and medication. Recent data supports its effectiveness, leading to FDA approval of devices in late 2023. The discussion highlights challenges in making RDN more accessible, including the limited number of trained interventional physicians (approximately 14,000 in the U.S.), which poses a potential workforce issue. It emphasizes the need for endovascular specialists to develop specific skill sets for RDN, involving non-invasive assessments and the management of potential complications. The debate includes the future role of different medical specialties, training standards, and the guidelines necessary to effectively expand RDN services. The video concludes by discussing the importance of consensus among medical societies regarding patient selection and procedural guidance for RDN.

Keywords

hypertension

renal denervation

FDA approval

interventional physicians

medical training